Endurance Training in Hematologic Disease: Current Perspectives and Clinical Implications

Abstract

Endurance training, once considered contraindicated in hematologic disease due to concerns about exacerbating symptoms or complications, is now recognized as a valuable adjunct to traditional medical management. Growing evidence from recent clinical trials and observational studies suggests that prescribed endurance exercise can improve functional capacity, quality of life, and even hematologic parameters in select patient populations. This review evaluates the epidemiology, pathophysiology, clinical features, and management of hematologic diseases in the context of endurance training, synthesizing recent guideline recommendations and highlighting emerging therapies and practical strategies for safe implementation.

Introduction

Hematologic diseases—including anemias, hemoglobinopathies, myeloproliferative disorders, and hematologic malignancies—frequently impair physical performance and quality of life. Fatigue, reduced oxygen-carrying capacity, and treatment-related adverse effects often limit exercise tolerance in this population. However, contemporary research demonstrates that carefully tailored endurance training protocols can mitigate symptom burden, enhance cardiorespiratory fitness, and improve psychosocial outcomes. The integration of endurance exercise into the care of patients with hematologic conditions requires nuanced understanding of disease mechanisms, individualized risk assessment, and evidence-based program design.

Epidemiology / Disease Burden

Hematologic diseases represent a significant global health burden, with anemias affecting over 1.6 billion individuals worldwide and hematologic malignancies accounting for approximately 10% of all cancers. Chronic fatigue and reduced exercise tolerance are among the most debilitating symptoms reported by patients, contributing to functional decline, increased healthcare utilization, and diminished quality of life. The prevalence of physical inactivity is particularly high in this population, compounding the risk of cardiovascular comorbidities and further reducing functional reserve. Epidemiological data underscore the need for effective, non-pharmacological interventions to address these challenges.

Pathophysiology

The pathophysiologic basis for exercise intolerance in hematologic disease is multifactorial. In anemia and hemoglobinopathies, reduced hemoglobin levels impair oxygen delivery to skeletal muscle, limiting aerobic metabolism and leading to early fatigue. In myeloproliferative and lymphoproliferative disorders, systemic inflammation, cytokine dysregulation, and marrow dysfunction contribute to both anemia and muscle wasting. Treatment regimens such as chemotherapy or immunosuppression can exacerbate fatigue, induce cardiotoxicity, or precipitate cytopenias, further restricting exercise capacity. Understanding these mechanisms is critical for developing safe and effective endurance training programs tailored to the unique needs of this population.

Risk Factors

Several patient-specific and disease-related factors modulate the risks and benefits of endurance training in hematologic disease. Advanced age, severe anemia (hemoglobin <8 g/dL), active infection, uncontrolled bleeding, and recent thromboembolic events represent relative contraindications to unsupervised exercise. Additional considerations include the presence of cardiopulmonary disease, musculoskeletal limitations, and ongoing cytotoxic therapy. Risk stratification should be individualized, with close interdisciplinary collaboration between hematologists, physiatrists, and exercise specialists to ensure optimal safety and efficacy.

Clinical Features

Clinical manifestations of hematologic disease that impact exercise tolerance include persistent fatigue, dyspnea, exercise-induced tachycardia, orthostatic intolerance, and muscle weakness. In some conditions, such as sickle cell disease, exertion may precipitate vaso-occlusive crises or rhabdomyolysis. Conversely, in diseases characterized by hyperviscosity or thrombophilia, there is an increased risk of exercise-associated thrombotic events. Comprehensive clinical assessment—including laboratory evaluation, cardiopulmonary testing, and functional capacity measurement—is essential prior to initiating endurance training.

Diagnosis

Diagnosis of hematologic disease relies on a combination of clinical evaluation, laboratory testing (complete blood count, reticulocyte count, peripheral smear), bone marrow examination, and molecular or cytogenetic studies when indicated. In the context of exercise prescription, additional assessment of baseline exercise tolerance (e.g., six-minute walk test, VO2 max testing) provides valuable information for program tailoring and monitoring of therapeutic response.

Treatment & Management

Standard management of hematologic disease involves disease-specific pharmacologic therapy (e.g., transfusions, chemotherapy, targeted agents) alongside supportive care. Endurance training is now recognized as a safe and effective adjunct in selected patients, with protocols typically emphasizing low- to moderate-intensity aerobic activity (e.g., walking, cycling, swimming) performed 3-5 times weekly. Exercise programs must be individualized, with gradual progression and close monitoring for adverse effects. Key management principles include optimizing hemoglobin levels, controlling symptoms, and ensuring adequate hydration and nutrition.

Recent Advances / Emerging Therapies

Recent research highlights the potential for endurance training to induce favorable hematologic and systemic adaptations, including improved erythropoietic response, enhanced endothelial function, reduced inflammation, and ameliorated chemotherapy-induced fatigue. Trials in patients with leukemia, lymphoma, and sickle cell disease demonstrate significant improvements in aerobic fitness, muscle strength, and health-related quality of life, with minimal adverse events when programs are carefully supervised. Emerging therapies—such as erythropoiesis-stimulating agents and novel targeted drugs—may further enhance the safety and feasibility of exercise interventions in high-risk populations.

Guideline Recommendations

Consensus guidelines from organizations such as the American Society of Hematology and the American College of Sports Medicine advocate for the integration of structured exercise programs into the care of patients with stable hematologic disease. Key recommendations include pre-exercise risk assessment, individualized exercise prescription, and multidisciplinary collaboration. Monitoring for adverse events, such as symptomatic anemia, bleeding, or arrhythmia, is critical. In the absence of contraindications, endurance training is considered both safe and beneficial, with evidence supporting improvements in physical function, fatigue, and overall well-being.

Conclusion

Endurance training represents a promising adjunct to conventional therapy in hematologic disease, offering clinically meaningful benefits in functional capacity, symptom control, and quality of life. Successful implementation requires careful patient selection, individualized program design, and ongoing interdisciplinary collaboration. As the evidence base continues to expand, integration of endurance exercise into standard care pathways holds the potential to transform outcomes for patients with hematologic disease, emphasizing the importance of holistic, patient-centered management.